Continuous Professional Education Programme for Registered Nurses and Midwives to administer **Priorix or MMRvaxPro Vaccine** under the Medicine Protocol to children/students in Primary and/or Second Level Schools through a School Immunisation Programme
Medicine Protocol

This Medicine Protocol is a specific written instruction for the administration of measles, mumps and rubella (live) vaccine

(Priorix or MMRvaxPro),
to groups of children/student who may not be individually identified before presentation for treatment.
Clinical Criteria

Active immunisation against and prevention of measles, mumps and rubella infections.
Circumstances in which the Medicine Protocol applies

• The Schools Immunisation Programme is delivered annually by the HSE.
• The aim of the immunisation programme is to complete the measles, mumps and rubella vaccine, (live) two dose schedule for children
  - 1<sup>st</sup> dose at 12 months
  - 2<sup>nd</sup> dose at 4 to 5 years

• Please note: If the 1<sup>st</sup> dose of Priorix / MMRvaxPro vaccine is given to a child in junior infants or age equivalent under this Medicine Protocol, a 2<sup>nd</sup> dose of MMR should be given at least four weeks later at a mop-up clinic.
• This Medicine Protocol also applies in MMR catch-up campaigns and outbreak situations as recommended by NIAC, (2017)
Inclusion Criteria for MMRvaxPro / Priorix

• Children/students in primary/second level schools or age equivalent (e.g. home schooled, special school).

• Children/students with a valid consent.
Exclusion Criteria for MMRvaxPro/Priorix

- Any child/student who has had an **anaphylactic or hypersensitivity** reaction to a previous dose of Priorix/MMRvaxPro or any of its components including neomycin or gelatin (refer to protocol).

- **Acute febrile illness.** The presence of a minor infection such as a mild upper respiratory infection or low grade fever is not a contraindication for immunisation.

- History of **thrombocytopenia** within six weeks of receiving MMR vaccine.

- **Contraindication to intramuscular injection** (haematological disorder/coagulation disorder)
Exclusion Criteria cont....

- Immunocompromised children/student either due to disease or treatment
- Active untreated tuberculosis

- **Children/Students who received:**
  - low-dose immunoglobulin within the previous 5 months
  - red-cell transfusion within 6 months
  - high-dose immunoglobulin within 11 months.
  - Varicella or Yellow Fever live vaccines within the previous 4 weeks.

- **Pregnancy** where applicable.

**Note**

- Child/student on topical **tacrolimus** within the last 28 days is NOT a contraindication to MMR (NIAC 2018).
Priorix Vaccine: Product Information

• Details of the most current and update information of the SmPC and other data is available on the website https://www.hpra.ie
What are the constituents of Priorix Vaccine?

- After reconstitution, Priorix (0.5 ml) contains:
  - Live attenuated measles vaccine (Schwarz strain)¹
  - Live attenuated mumps virus (RIT 4385 strain)²
  - Live attenuated rubella virus (Wistar RA 27/3 strain)³

  ¹Produced in chick embryo cells
  ²Produced in human diploid (MRC-5) cells
  ³Cell Culture Infective Dose 50%

For a full list of excipients please see https://www.hpra.ie
Nature and contents of pack:

- Priorix comes in packs of 10

- MMR component (powder) in vial (Type I glass) with rubber stopper and 0.5 ml of solvent for solution in pre filled syringe (Type I glass) with a rubber plunger stopper.

- Unattached needles of 25mm X 2

- **Prior to reconstitution** the lyophilised MMR component is a white to slightly pink powder and the solvent is a clear, colourless solution.

- The reconstituted vaccine may vary in colour from clear peach to fuchsia pink.
MMRvaxPro Vaccine: Product Information

Details of the most current and update information of the SmPC and other data is available on the website

https://www.hpra.ie
What are the constituents of MMRvaxPro Vaccine?

For a full list of excipients please see https://www.hpra.ie
Nature and Contents of Pack:

- Powder in a Vial (Type1 glass) with a stopper (butyl rubber)

- Solvent in a pre-filled syringe (Type1 glass) with plunger stopper (chlorobutyl rubber) and tip cap (styrene-butadienerubber).

- MMRvaxPro is available in one single dose vial (powder) and one single dose 0.5 ml pre-filled syringe (solvent) with two unattached needles.
Possible Side Effects

- **Very common** (more than 1 per 10 doses of vaccine):
  - Redness at injection site.
  - Fever >38°C

- **Common** (more than 1 in 100 doses and less than 1 in 10 doses)
  - Rash
  - Pain and swelling at injection site
  - Fever >39°C
  - Upper respiratory tract infection

- For a full list of side effects refer to [https://www.hpra.ie](https://www.hpra.ie)
Possible Side Effects

**Uncommon** (more than 1 in 1000 doses and less than 1 in 100 doses):

- Nasal congestion and sore throat;
- Upper respiratory tract infection or viral infection;
- runny nose.

- Diarrhoea, vomiting.
- Hives.
- Injection-site rash.

**Rare** (more than 1 in 10,000 doses and less than 1 in 1,000):

- Febrile convulsions
- Allergic reactions
- Mumps-like condition (‘mini-mumps’) with swelling of the testicles and salivary glands 3 weeks post vaccination
- Measles-like condition (‘mini-measles’) with mild pyrexia and rash 6-10 days post vaccination.
- Rubella-like condition with lymph node swelling, arthralgia and rash 2-4 weeks post vaccination.
Any Questions?